Pacira BioSciences, Inc. (PCRX) company profile
Close on Nov 16, 2026Market cap $1.45BP/E 104.2Yield –
About Pacira BioSciences
Pharmaceutical Preparations, SIC 2834
Pacira BioSciences develops and commercializes non-opioid pain therapies for patients undergoing surgical procedures or managing chronic joint conditions. The company provides three primary commercial products: EXPAREL, a long-acting injectable local analgesic for postsurgical pain; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and iovera, a handheld cryoanalgesia device that administers targeted cold temperatures to relieve nerve pain without drugs. Its therapies serve surgical patients, including adult and pediatric populations, as well as individuals suffering from osteoarthritis and chronic musculoskeletal pain.
The business operates corporate headquarters and principal executive offices in Brisbane, California. It maintains commercial authorization and clinical registrations across the United States, Canada, and the European Union. In addition to commercializing products for hospital outpatient departments and ambulatory surgery centers, the enterprise oversees registry studies across 15 participating clinical sites in the United States.
Summary of the business section of Pacira BioSciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pacira BioSciences, Inc.
- Founded
- 2006
- Headquarters
- Brisbane, CA
- Address
- 2000 Sierra Point Parkway, Suite 900 94005
- Phone
- (650) 242-8052
- Website
- pacira.com
- Employees
- 829, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Short Hills, NJ
Stock & identifiers
- Ticker
- PCRX
- Exchange
- Nasdaq
- IPO date
- Feb 3, 2011
- Shares outstanding
- 40M, Aug 3, 2026
- Public float
- $757.50M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1396814
- CUSIP
- 695127100
- ISIN
- US6951271005
- FIGI
- BBG0018FQNS6
- Share class FIGI
- BBG001S77N12
- LEI
- 549300P56LERYBDHCF69
- EIN
- 51-0619477
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Frank D. Lee | Chief Executive Officer, Director | 0 |
| Jonathan Slonin | Chief Medical Officer | 0 |
| Shawn Cross | Chief Financial Officer | 0 |
| Kristen Williams | Chief Administrative Officer | 0 |
| Brendan Teehan | Chief Commercial Officer | 0 |
| Lauren Riker | Senior Vice President, Finance | 0 |
| Daryl Gaugler | Chief Operating Officer | 115,443 |
| Marcelo Bigal | Director | 0 |
| Michael J. Yang | Director | 0 |
| Thomas G. Wiggans | Director | – |
| Laura Brege | Director | 0 |
| Mark Froimson | Director | 0 |
| Christopher Christie | Director | 0 |
| Samit Hirawat | Director | 0 |
| Alethia Young | Director | 0 |
| Mark A. Kronenfeld | Director | 31,065 |
| Abraham Ceesay | Director | 9,039 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 David Stack | $727.38K | -$2.65M | $2.59M | $42 | $94 |
| FY2024 Frank Lee | $15.94M | $10.19M | $2.59M | $42 | $94 |
| FY2023 | $6.88M | $4.21M | $1.54M | $74 | $91 |
| FY2022 | $6.85M | $887.12K | $2.03M | $85 | $90 |
| FY2021 | $6.94M | $5.46M | $2.06M | $133 | $140 |
| FY2020 | $9.34M | $13.55M | $2.45M | $132 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Frank Lee Chief Executive Officer | $896.54K | $688.50K | $3.18M | $9.61M | $648.24K | $919.10K | $15.94M | – |
| David Stack Former Chief Executive Officer | $634.04K | $2.19K | – | – | – | $91.15K | $727.38K | -89% |
| Shawn Cross Chief Financial Officer | $100.96K | $48.56K | $1.24M | $1.35M | – | $3.72K | $2.74M | – |
| Lauren Riker Former Interim Chief Financial Officer | $374.56K | $271.72K | $612.61K | – | $159.19K | $20.83K | $1.44M | – |
| Charles A. Reinhart, III Former Chief Financial Officer | $374.17K | $172.26K | $350.47K | – | – | $387.64K | $1.28M | -10% |
| Kristen Williams Chief Administrative Officer and Secretary | $519.26K | $246.81K | $2.61M | – | $220.75K | $15.61K | $3.61M | +125% |
| Daryl Gaugler Executive Vice President, Commercial Operations | $511.81K | $236.80K | $2.61M | – | $217.52K | $20.83K | $3.59M | +134% |
| Jonathan Slonin Chief Medical Officer | $535.00K | $247.44K | $1.72M | $131.04K | $227.30K | $20.83K | $2.88M | +81% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 3, 2011
- Offer price
- $7.00
- Securities offered
- 6,000,000
- Gross proceeds
- $42.00M
- Exchange
- Nasdaq
- First trading day
- Feb 3, 2011
- First-day close
- $7.02+0.3%
- Lock-up ends (est.)
- Aug 2, 2011
“Per share Total Price to the public $ 7.00 $ 42,000,000 Underwriting discounts and commissions $ 0.49 $ 2,940,000 Proceeds to us (before expenses) $ 6.51 $ 39,060,000 Certain of our existing principal stockholders and their affiliated entities have indicated an interest in purchasing an aggregate of up to $7.5 mill”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 829 employees, of which 825 were full-time and four were part-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 30, 2026 | Tender offer | Third-party tender offer for the company's shares |
| Nov 19, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 22, 2021 | Tender offer | Third-party tender offer for the company's shares |
| Apr 9, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 9, 2019 | Name change | Name changed from Pacira Pharmaceuticals, Inc. to Pacira BioSciences, Inc. |
| Feb 26, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 18, 2015 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 3, 2011 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 28, 2011 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 5, 2008 | Name change | Name changed from PACIRA INC to Pacira Pharmaceuticals, Inc. |
| Apr 16, 2007 | Name change | Name changed from Blue Acquisition Corp to PACIRA INC |
See a number that looks wrong?